BidaskClub downgraded shares of Puma Biotechnology (NASDAQ:PBYI) from a buy rating to a hold rating in a research note published on Tuesday.
PBYI has been the topic of several other research reports. Cowen cut Puma Biotechnology from an outperform rating to a market perform rating and dropped their price objective for the stock from $123.00 to $68.00 in a research note on Wednesday, January 24th. Credit Suisse Group set a $106.00 price objective on Puma Biotechnology and gave the stock a buy rating in a research note on Friday, March 2nd. Zacks Investment Research cut Puma Biotechnology from a hold rating to a sell rating in a research note on Monday, January 15th. Stifel Nicolaus set a $95.00 price objective on Puma Biotechnology and gave the stock a buy rating in a research note on Friday, March 9th. Finally, Barclays lowered their target price on Puma Biotechnology from $92.00 to $90.00 and set an overweight rating for the company in a report on Friday, March 2nd. One research analyst has rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company. Puma Biotechnology presently has an average rating of Hold and a consensus price target of $103.11.
Shares of NASDAQ:PBYI opened at $66.40 on Tuesday. Puma Biotechnology has a 52-week low of $28.35 and a 52-week high of $136.90. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.79 and a current ratio of 1.82.
Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.98) by $0.27. The firm had revenue of $21.60 million during the quarter, compared to the consensus estimate of $20.83 million. During the same period last year, the company earned ($1.22) EPS. equities analysts predict that Puma Biotechnology will post -4.07 earnings per share for the current fiscal year.
In other Puma Biotechnology news, SVP Richard Paul Bryce sold 1,860 shares of the company’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $92.75, for a total transaction of $172,515.00. Following the completion of the sale, the senior vice president now owns 25,379 shares in the company, valued at $2,353,902.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Alan H. Auerbach sold 10,692 shares of the company’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $92.75, for a total value of $991,683.00. Following the sale, the insider now owns 4,155,931 shares of the company’s stock, valued at approximately $385,462,600.25. The disclosure for this sale can be found here. 21.10% of the stock is owned by corporate insiders.
Institutional investors have recently bought and sold shares of the business. Xact Kapitalforvaltning AB purchased a new stake in shares of Puma Biotechnology during the 4th quarter valued at $292,000. J. Goldman & Co LP lifted its holdings in shares of Puma Biotechnology by 94.1% during the 4th quarter. J. Goldman & Co LP now owns 31,829 shares of the biopharmaceutical company’s stock valued at $3,146,000 after purchasing an additional 15,429 shares during the last quarter. Doheny Asset Management CA purchased a new stake in shares of Puma Biotechnology during the 4th quarter valued at $870,000. MetLife Investment Advisors LLC purchased a new stake in shares of Puma Biotechnology during the 4th quarter valued at $1,363,000. Finally, Endurant Capital Management LP lifted its holdings in shares of Puma Biotechnology by 39.7% during the 4th quarter. Endurant Capital Management LP now owns 29,900 shares of the biopharmaceutical company’s stock valued at $2,956,000 after purchasing an additional 8,500 shares during the last quarter. Institutional investors own 95.95% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/14/puma-biotechnology-pbyi-downgraded-to-hold-at-bidaskclub.html.
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.